Gilead Sciences Inks $247M Deal For HIV Antitrust Claims

By Matthew Perlman · August 10, 2023, 5:32 PM EDT

Gilead has agreed to pay direct purchasers of its HIV medications $246.8 million, ending claims the pharmaceutical company cut a deal with Teva to delay generic versions after reaching an initial...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Brief

Case Information

Case Title

In re HIV Antitrust Litigation

Case Number

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

May 14, 2019

Recent Articles By Matthew

November 21, 2024
Nurse Staffing Exec Can't Trim Fraud Charge In Antitrust Case
November 20, 2024
PBMs Sue To Block FTC's In-House Insulin Pricing Case
November 07, 2024
Teva Can't End Inhaler Antitrust Suit But Gets Claim Nixed
November 01, 2024
Health Data Co. Urges 4th Circ. To Keep Access Open
October 31, 2024
Drug Cos. To Pay $49M For State-Led Generic Pricing Claims
October 30, 2024
Ohio PBM Case Will Wait For High Court Ruling
October 24, 2024
PBMs Want Separate FTC Hearings Over Insulin Prices
October 21, 2024
NC Justices Revive Challenge To Hospital Competition Law
October 15, 2024
FTC Wants More Info On $1.36B Home Healthcare Deal
October 07, 2024
Justices Won't Hear Shkreli's Bid To Undo $64M Disgorgement